BeiGene, Ltd. (BGNE)

Market Cap	14.93B
Revenue (ttm)	2.46B
Net Income (ttm)	-881.71M
Shares Out	107.43M
EPS (ttm)	-0.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	201,776
Open	135.75
Previous Close	130.94
Day's Range	134.68 - 142.22
52-Week Range	126.97 - 266.67
Beta	0.63
Analysts	Buy
Price Target	256.26 (+84.37%)
Earnings Date	May 6, 2024

About BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 3, 2016
• Employees: 10,600
• Stock Exchange: NASDAQ
• Ticker Symbol: BGNE

Financial Performance

In 2023, BeiGene's revenue was $2.46 billion, an increase of 73.65% compared to the previous year's $1.42 billion. Losses were -$881.71 million, -56.00% less than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for BGNE stock is "Buy." The 12-month stock price forecast is $256.26, which is an increase of 84.37% from the latest price.

Price Target

$256.26

(84.37% upside)

Analyst Consensus: Buy